Form 4: Johnson & Johnson Subsidiary Reduces CVRx Stake

Johnson & Johnson's subsidiary, JJDC, reported the sale of 52,532 shares of CVRx, Inc. common stock in early November 2025.

Summary

• Johnson & Johnson, through its wholly-owned subsidiary Johnson & Johnson Innovation JJDC, Inc. (JJDC), reported the sale of CVRx, Inc. common stock.
• On November 6, 2025, JJDC sold 52,332 shares at a weighted average price of $10.21 per share, with prices ranging from $10.00 to $10.49.
• On November 7, 2025, JJDC sold an additional 200 shares at a price of $10.00 per share.
• Following these transactions, JJDC indirectly beneficially owns 4,050,898 shares of CVRx, Inc. common stock.
• Johnson & Johnson is a 10% owner and has a director relationship with CVRx, Inc.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a significant institutional investor reducing its stake, which can signal a lack of conviction or a strategic shift, despite the relatively small size of the sale compared to the total holding.

Positives

• The sales were executed at prices between $10.00 and $10.49, indicating a specific valuation for the shares at the time of sale.

Negatives

• A significant shareholder, Johnson & Johnson (through JJDC), reduced its stake in CVRx, Inc. by 52,532 shares.

Future Outlook

NA

Industry Context

This transaction reflects a portfolio adjustment by a major strategic investor (Johnson & Johnson) in a medical device company (CVRx, Inc.). While the sale is relatively small compared to JJDC's remaining stake, it could be interpreted by the market as a slight reduction in conviction or a rebalancing of investment priorities within the healthcare sector.

Related Party Transactions

• The transactions involve Johnson & Johnson, a 10% owner and director of CVRx, Inc., selling shares through its wholly-owned subsidiary, Johnson & Johnson Innovation JJDC, Inc. This constitutes a related party transaction as J&J has significant influence over CVRx.

Stakeholder Impact

• Shareholders of CVRx, Inc. may view the reduction in stake by a major institutional investor like Johnson & Johnson negatively, potentially leading to downward pressure on the stock price.
• Johnson & Johnson's investment portfolio is being rebalanced, which could impact its strategic focus on CVRx, Inc. going forward.

Key Dates

Recommendation

While the sale by Johnson & Johnson's subsidiary is a negative signal, the amount sold is a small fraction of their total holding. It could be a portfolio rebalancing rather than a complete loss of confidence. Investors should hold and monitor future insider activity and company performance before making a definitive buy or sell decision.

Keywords

CVRx Inc., CVRX, Johnson & Johnson, JJDC, Insider Sale, Form 4, Beneficial Ownership, Stock Transaction, Medical Devices